STEAP4 modulates cell proliferation and oxidative stress in benign prostatic hyperplasia

Benign prostatic hyperplasia (BPH) is a quite common chronic disease plagued elderly men and its etiology remains unclear. It was reported that the six-transmembrane epithelial antigen of prostate 4 (STEAP4) could modulate cell proliferation/Apoptosis ratio and oxidative stress in cancers. Our current study aimed to explore the expression, biological function, and underlying mechanism of STEAP4 in BPH progress. Human prostate tissues and cell lines were utilized. qRT-PCR and immunofluorescence staining were employed. STEAP4 knockdown (STEAP4-KD) or STEAP4 overexpression (STEAP4-OE) cell models were established. Cell proliferation, cell cycle, Apoptosis, and Reactive Oxygen Species (ROS) were determined by cell counting kit-8 (CCK-8) assay and flow cytometry. Apoptosis-related proteins and antioxidant Enzymes were identified by Western Blot. In addition, the epithelial-mesenchymal transition (EMT) process and fibrosis biomarker (collagen I and α-SMA) were analyzed. It was indicated that STEAP4 was mainly located in the prostate epithelium and upregulated in BPH tissues. STEAP4 deficiency induced Apoptosis and inhibited cell survival, but had no effect on the cell cycle, fibrosis, and EMT process. In addition, ROS changes were observed in the STEAP4-KD model. Consistently, overproduction of STEAP4 suppressed Apoptosis and promoted cell proliferation, as well as facilitated ROS production. We further examined Akt / mTOR, p38MAPK / p-p38MAPK, and Wnt/ β-catenin signaling pathway and demonstrated that STEAP4 regulated the proliferation and Apoptosis of prostate cells through Akt / mTOR signaling, rather than p38MAPK / p-p38MAPK and Wnt/ β-catenin pathways. Furthermore, activating Akt / mTOR signaling with SC79 significantly reversed Apoptosis triggered by STEAP4 deficiency, whereas suppressing Akt / mTOR signaling with MK2206 reduced the increase of cell viability triggered by STEAP4 overproduction. Our original data demonstrated that STEAP4 is crucial in the onset and progression of prostate hyperplasia and may become a new target for the treatment of BPH.

Benign prostatic hyperplasia; Cell apoptosis; Six-transmembrane epithelial antigen of prostate 4.